SEER Inquiry System - Search

Histology--Brain and CNS: What is the histology code of a primary papillary epithelial tumor of the sella (PPETS)?  See Discussion.

Solid Tumor Rules/Histology--Thyroid:  What is the histology code for sclerosing mucoepidermoid carcinoma with eosinophilla in the left thyroid and papillary thyroid carcinoma in the right thyroid?  See Discussion.

Reportability/Histology--Eye:  Is “squamous mucosa with high grade dysplasia” equivalent to a diagnosis of “high grade squamous dysplasia?” See Discussion.

Laterality--Brain and CNS: Can Laterality be coded as 5 (midline) for a sella turcica meningioma (or tuberculum sellae meningioma) when no other statement regarding tumor laterality is documented? See Discussion.

Primary Site/Histology--Intrahepatic Duct:  How are primary site and histology coded for cholangiocarcinoma cases when the pathology only shows a liver tumor and other involvement.  See Discussion.

First Course Treatment/Radiation Therapy:  How should Lutathera be coded? CoC states XRT- Radioisotopes and SEER states Other Treatment.

First Course Treatment/Neoadjuvant Therapy--Melanoma:  How are the three Neoadjuvant Therapy data items (Neoadjuvant Therapy, Neoadjuvant Therapy--Clinical Response, Neoadjuvant Therapy--Treatment  Effect) coded when a patient is diagnosed with melanoma in the lymph nodes with no primary skin site identified? The physician gives immunotherapy as neoadjuvant therapy with planned and carried out surgical resection of involved lymph nodes following completion of immunotherapy. There is no "planned definitive surgical resection of the primary site" as no primary site was found,

Solid Tumor Rules (2018/2021)/Histology--Head & Neck:  What is the histology code for a uvula (C052) primary with histology of squamous cell carcinoma, conventional (keratinizing) and p16 result is negative? See Discussion.

First Course Treatment/Immunotherapy--Other Therapy:  Should IMC-A12 (Cixutumumab) be coded as Immunotherapy/Biological Response Modifier (BRM) treatment?  See Discussion.

Solid Tumor Rules/Multiple Primaries--Head and Neck:  Is a patient with 2020 neck mass, squamous cell carcinoma (SCC), p16-negative, who then had a biopsy of the right tonsil (C09.9) in July 2022, SCC p16-positive, one or two primaries? Is this coded to 8070/3 using pre-2022 rules or a new, second primary p16-positive, 8085/3.  See Discussion.